Anavex Life Sciences
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 |
|---|---|---|
Revenue | $0 | $0 |
EBITDA | -5,663 | -6,485 |
Net Income | -5,681 | -9,827 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -7,151 | -8,604 |
Cash | 131,749 | 102,577 |
Basic Shares | 89,029 | 85,893 |
Annual Financials
| Values in thousands | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -46,377 | -43,002 | -47,498 | -47,620 |
EBIT | -45,293 | -47,498 | -47,619 | |
Net Income | -46,377 | -43,002 | -47,491 | -47,978 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,949 | |||
Free Cash Flow | -39,044 | -30,812 | -27,785 | -24,238 |
Cash | 102,577 | 132,187 | 151,024 | 149,157 |
Basic Shares | 85,289 | 83,468 | 79,788 | 76,910 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.08 |
2026-03-31 | -$0.13 |
2025-12-31 | -$0.06 |
2025-09-30 | -$0.11 |